Effects of Smoking on Nortriptyline Plasma Concentrations in Depressed Patients

Publisher Website
Google Scholar
Abstract
The pharmacokinetic parameters of half-life, volume of distribution, and steady-state nortriptyline plasma concentration normalized to a 100-mg/day maintenance dose were calculated in nine smokers and 15 nonsmokers. The mean normalized total nortriptyline concentration for the smokers of 118 ± 33 ng/ml was significantly lower than the nonsmokers' mean value of 158 ± 35 ng/ml. The mean normalized free plasma concentrations for the smokers of 11.4 ± 3.5 ng/ml was not different from the nonsmokers' mean concentrations of 11.5 ± 2.6 ng/ml. The smokers had a slightly higher percentage free drug values of 10.2 ± 4.0% (p = 0.08) as contrasted to 7.4 ± 1.5% free nortriptyline for the nonsmokers. The nortriptyline half-life figures for both the free and total drug concentrations did not differ. Multiple linear regression analysis utilizing age, smoking status, sex, liver function, and the presence or absence of enzyme-inducing or -inhibiting drugs as the potential independent variables and percentage free nortriptyline or total nortriptyline concentration as the dependent variable, found that smoking status explained 21% of the variation in the percentage free nortriptyline in the patients and 26% of the variation in the total nortriptyline concentrations. These preliminary data suggest that smokers ideally should be dosed at the lower end of the nortriptyline therapeutic range, whereas nonsmokers should be dosed at the upper end to maximize the antidepressant effect and minimize adverse effects.